Syndax Pharmaceuticals Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+4.40%
vs ±7.7% implied · ×0.57
shaded = implied · ▲▼ = realized
Fund move
Fund move
No thesis.
Syndax Pharmaceuticals Inc
13.63
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | BlackRockBlackRockindex-like | $197.2M | 8.30% | +9.27% | |
| 2 | Kynam Capital ManagementKynam | $176.0M | 7.41% | 0.00% | |
| 3 | Goldman Sachs GroupGoldman Sachs | $128.1M | 5.39% | +17.30% | |
| 4 | State StreetState Streetindex-like | $123.7M | 5.21% | +27.73% | |
| 5 | Bank of AmericaBank of America | $88.4M | 3.72% | −4.82% | |
| 6 | Vanguard Capital ManagementVanguardindex-like | $85.9M | 3.61% | +2.76% | |
| 7 | Deerfield ManagementDeerfield | $82.6M | 3.48% | 0.00% | |
| 8 | Eversept PartnersEversept Partners | $61.2M | 2.58% | −3.03% | |
| 9 | Geode Capital ManagementGeodeindex-like | $56.5M | 2.38% | +19.80% | |
| 10 | Hood River Capital ManagementHood River | $56.1M | 2.36% | +8.92% | |
| 11 | Kingdon Capital ManagementKingdon | $54.6M | 2.30% | 0.00% | |
| 12 | Franklin ResourcesFranklin Resources | $50.0M | 2.10% | +6.34% | |
| 13 | Millennium ManagementMillennium | $44.9M | 1.89% | +929.43% | |
| 14 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $42.0M | 1.77% | +10.63% | |
| 15 | UBS GroupUBS | $41.4M | 1.74% | +64.15% | |
| 16 | Elmind CapitalElmind Capital | $40.6M | 1.71% | 0.00% | |
| 17 | BNP Paribas Investment PartnersBNP Paribas Investment Partners | $39.1M | 1.65% | +3.33% | |
| 18 | Candriam Luxembourg S.C.A.Candriam Luxembourg S.C.A. | $37.0M | 1.56% | +83.29% | |
| 19 | Soleus Capital ManagementSoleus | $35.6M | 1.50% | −5.73% | |
| 20 | Two Sigma InvestmentsTwo Sigma | $34.5M | 1.45% | −0.09% | |
| 21 | Orbimed AdvisorsOrbimed | $33.7M | 1.42% | +60.24% | |
| 22 | NuveenNuveenindex-like | $29.8M | 1.26% | −8.70% | |
| 23 | MPM Oncology Impact ManagementMPM Oncology Impact | $29.2M | 1.23% | −0.54% | |
| 24 | Aisling Capital ManagementAisling | $28.8M | 1.21% | 0.00% | |
| 25 | Woodline PartnersWoodline Partners | $27.3M | 1.15% | 0.00% |
242 managers report $2.4B of Syndax Pharmaceuticals on form 13F for the quarter ended Jun 30 '26. 38 of them hold 80% of it; BlackRock is largest at 8.30%.
Linked news
Expected move
Inputs8Q avg ±9.6%·×0.63·cheap
straddle ±13.5%
spot 13.65exp Nov 20ATM strike 14ATM straddle 2.17IV 82%